IT1226800B
(it)
*
|
1988-09-16 |
1991-02-19 |
Prodotti Formenti |
Composizioni farmaceutiche orali contenenti sali di destrorfano.
|
US5506231A
(en)
*
|
1989-03-31 |
1996-04-09 |
The Children's Medical Center Corporation |
Treatment of aids dementia, myelopathy and blindness
|
US5334618A
(en)
*
|
1991-04-04 |
1994-08-02 |
The Children's Medical Center Corporation |
Method of preventing NMDA receptor-mediated neuronal damage
|
WO1991002810A1
(en)
*
|
1989-08-09 |
1991-03-07 |
The Children's Medical Center Corporation |
Nmda oxidizing agents for protecting neurons from injury
|
WO1991002523A1
(en)
*
|
1989-08-17 |
1991-03-07 |
The Children's Medical Center Corporation |
Glutamatergic amino acid agonists and antagonists
|
PT95069B
(pt)
*
|
1989-08-24 |
1997-10-31 |
Searle & Co |
Processo para a preparacao de (+)-isomeros de derivados de endoetano/endoetanoepoximofinano, uteis como agentes anti-tussicos
|
EP0424179A3
(en)
*
|
1989-10-20 |
1991-12-27 |
John William Olney |
Use of combined excitatory amino acid and cholinergic antagonists to prevent neurological deterioration
|
US5013540A
(en)
*
|
1989-11-30 |
1991-05-07 |
Board Of Regents, The University Of Texas System |
Using NMDA receptor antagonists to reduce damage due to laser treatment
|
US5229394A
(en)
*
|
1990-07-30 |
1993-07-20 |
Arch Development Corporation |
Method for treatment of amyotrophic lateral sclerosis comprising administration of dmp
|
US5089517A
(en)
*
|
1990-08-03 |
1992-02-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Neuroprotection by indolactam v and derivatives thereof
|
US5145862A
(en)
*
|
1990-08-16 |
1992-09-08 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Method of resisting neurodegenerative disorders
|
US5455279A
(en)
*
|
1991-04-19 |
1995-10-03 |
The Children's Medical Center Corporation |
Regimen method of mediating neuronal damage using nitroglycerine
|
US5614560A
(en)
*
|
1991-04-04 |
1997-03-25 |
Children's Medical Center Corporation |
Method of preventing NMDA receptor-mediated neuronal damage
|
US6071876A
(en)
*
|
1991-04-19 |
2000-06-06 |
Children's Medical Center Corporation |
Method of preventing NMDA receptor complex-mediated neuronal damage
|
JPH06506690A
(ja)
*
|
1991-04-19 |
1994-07-28 |
ザ チルドレンズメディカルセンター コーポレーション |
Nmda受容体複合体に媒体されるニューロン障害の阻止方法
|
EP0531105B1
(en)
*
|
1991-09-03 |
1997-04-16 |
Carter-Wallace, Inc. |
Use of felbamate for the manufacture of a medicament for the treatment of neuropsychopharmacological disorders
|
AU651247B2
(en)
|
1991-09-06 |
1994-07-14 |
Mcneilab, Inc. |
Composition comprising a tramadol material and acetaminophen and its use
|
JPH07505908A
(ja)
*
|
1992-09-28 |
1995-06-29 |
マックセチーニ、マリア ルイザ |
Nmda受容体のアロステリックモジュレーター
|
US5854217A
(en)
|
1992-09-28 |
1998-12-29 |
Bearsden Bio, Inc. |
Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
|
TW264473B
(xx)
*
|
1993-01-06 |
1995-12-01 |
Hoffmann La Roche |
|
USRE39300E1
(en)
|
1993-01-28 |
2006-09-19 |
Virginia Commonwealth University Medical College Of Virginia |
Inhibiting the development of tolerance to and/or dependence on an addictive substance
|
US5321012A
(en)
*
|
1993-01-28 |
1994-06-14 |
Virginia Commonwealth University Medical College |
Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
|
CA2115792C
(en)
*
|
1993-03-05 |
2005-11-01 |
David J. Mayer |
Method for the treatment of pain
|
JP3348230B2
(ja)
*
|
1995-03-03 |
2002-11-20 |
アルゴス ファーマシューティカル コーポレーション |
尿失禁の治療用のデキシトルメトルファン又はデキシトルオルファンの使用
|
US5935606A
(en)
*
|
1995-07-31 |
1999-08-10 |
Sagen; Jaqueline |
Reversing excitotoxic CNS damage by cellular implantation
|
GB9522176D0
(en)
*
|
1995-10-30 |
1996-01-03 |
Iaf Biochem Int |
Morphinan derivatives having neuroprotective activity
|
US5824662A
(en)
|
1996-09-27 |
1998-10-20 |
Guilford Pharmaceuticals Inc. |
Treatment of global and focal ischemia using naaladase inhibitors
|
US6017903A
(en)
|
1996-09-27 |
2000-01-25 |
Guilford Pharmaceuticals Inc. |
Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
|
US6277825B1
(en)
|
1996-07-22 |
2001-08-21 |
University Of Utah Research Foundation |
Use of conantokins for treating pain
|
US6515103B1
(en)
|
1996-07-22 |
2003-02-04 |
University Of Utah Research Foundation |
Conantokins
|
WO1998003189A1
(en)
|
1996-07-22 |
1998-01-29 |
Cognetix, Inc. |
Use of conantokins
|
HUP0001062A3
(en)
|
1996-09-27 |
2001-09-28 |
Guilford Pharmaceuticals Inc B |
Pharmaceutical compositions of phosphinic acid derivatives having naaladase inhibitor acivity
|
GB9706753D0
(en)
*
|
1997-04-03 |
1997-05-21 |
Pharmacia & Upjohn Spa |
Aralkoxy-morphinan derivatives
|
HU1500214D0
(hu)
|
1997-12-22 |
2002-03-28 |
Euro Celtique Sa |
Opioid agonista és antagonista hatóanyagot tartalmazó gyógyszerkészítmény
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
JP2001526229A
(ja)
|
1997-12-22 |
2001-12-18 |
ユーロ−セルティーク,エス.エイ. |
オピオイド投薬剤形の乱用を防止する方法
|
OA12215A
(en)
|
2000-02-08 |
2006-05-09 |
Euro Celtique Sa |
Tamper-resistant oral opioid agonist formulations.
|
US6716449B2
(en)
|
2000-02-08 |
2004-04-06 |
Euro-Celtique S.A. |
Controlled-release compositions containing opioid agonist and antagonist
|
US6399574B1
(en)
|
2000-03-22 |
2002-06-04 |
University Of Utah Research Foundation |
Use of conantokins
|
US20020013331A1
(en)
*
|
2000-06-26 |
2002-01-31 |
Williams Robert O. |
Methods and compositions for treating pain of the mucous membrane
|
ES2361148T3
(es)
|
2001-05-11 |
2011-06-14 |
Endo Pharmaceuticals Inc. |
Forma de dosificación de opioides de liberación controlada resistente al abuso.
|
DE60230632D1
(de)
*
|
2001-07-18 |
2009-02-12 |
Euro Celtique Sa |
Pharmazeutische kombinationen von oxycodon und naloxon
|
IS7142A
(is)
|
2001-08-06 |
2004-02-05 |
Euroceltique S.A. |
Lyfjasamsetningar, sem innihalda morfíngerandaefni, ásamt losanlegu en hömdu mótlyfi
|
AU2002324624A1
(en)
*
|
2001-08-06 |
2003-02-24 |
Euro-Celtique S.A. |
Sequestered antagonist formulations
|
US20030044458A1
(en)
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
EP2425823A1
(en)
|
2002-04-05 |
2012-03-07 |
Euro-Celtique S.A. |
Pharmaceutical preparation containing oxycodone and naloxone
|
TWI326214B
(en)
|
2002-07-17 |
2010-06-21 |
Avanir Pharmaceuticals Inc |
Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
|
EP1558268A4
(en)
*
|
2002-09-17 |
2008-09-17 |
Univ New York |
METHODS FOR TREATING AGE-RELATED MEMORY ALTERATIONS (AAMI), LIGHT COGNITIVE DEFICITS (MCI) AND DEMENTIA USING CELL CYCLE INHIBITORS
|
EP1551372B8
(en)
*
|
2002-09-20 |
2018-08-01 |
Alpharma Pharmaceuticals LLC |
Sequestering subunit and related compositions and methods
|
US20040202717A1
(en)
*
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
TWI347201B
(en)
|
2003-04-21 |
2011-08-21 |
Euro Celtique Sa |
Pharmaceutical products,uses thereof and methods for preparing the same
|
WO2005112931A2
(en)
*
|
2004-05-12 |
2005-12-01 |
The Government Of The United States As Represented By The Secretary, Department Of Health And Human Services |
Methods related to the treatment of neurodegenerative and inflammatory conditions
|
EP1604666A1
(en)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
|
EP1702558A1
(en)
*
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Method and device for the assessment of bowel function
|
KR20080097443A
(ko)
*
|
2006-02-03 |
2008-11-05 |
아바니르 파마슈티컬스 |
덱스트로메토판 및 퀴니딘을 포함하는, 우울, 불안 및 신경퇴행성 장애 치료용 약제학적 조성물
|
EP2526932B1
(en)
|
2006-06-19 |
2017-06-07 |
Alpharma Pharmaceuticals LLC |
Pharmaceutical composition
|
US10300031B2
(en)
*
|
2007-08-06 |
2019-05-28 |
Trinity Laboratories Inc. |
Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
|
WO2009059048A2
(en)
*
|
2007-10-30 |
2009-05-07 |
The Regents Of The University Of Colorado |
(+)-opioids and methods of use
|
US8623418B2
(en)
*
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
US20100151014A1
(en)
*
|
2008-12-16 |
2010-06-17 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
US20100266645A1
(en)
*
|
2007-12-17 |
2010-10-21 |
Alfred Liang |
Pharmaceutical compositions
|
EP2317991B1
(en)
*
|
2008-07-07 |
2017-05-03 |
Euro-Celtique S.A. |
Use of opioid antagonists for treating urinary retention
|
MX347106B
(es)
|
2009-03-10 |
2017-04-12 |
Euro-Celtique S A * |
Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona.
|
CN105517551A
(zh)
|
2013-07-23 |
2016-04-20 |
欧洲凯尔特公司 |
用于在患有疼痛和导致肠生态失调和/或提高肠细菌移位风险之疾病的患者中治疗疼痛的羟考酮与纳洛酮的组合
|
AU2015327762C1
(en)
|
2014-10-03 |
2020-10-22 |
Lachesis Biosciences Limited |
Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders
|
EP4122919A1
(en)
|
2016-07-04 |
2023-01-25 |
Avanir Pharmaceuticals, Inc. |
Methods for the synthesis of deuterated dextromethorphan
|